Form D · Biotechnology
Mercy BioAnalytics, Inc.
Natick, MA · CIK 0001842887
Offering snapshot reported Feb 1, 2021 · SEC filing
- Reported sold
- $27.3M Offering amount: $27.3M
- Investors reported
- 57 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 17, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 1, 2021 | Initial | $27,277,694 | No comparison | 57 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-387942
Amount sold includes $5,277,703.00 from conversion of promissory notes.
Source: Form D, filed Feb 1, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Blavin | Director, Executive |
| Stanley Lapidus | Director |
| Paul Meister | Director |
| Sonja Hoel Perkins | Director |
| Joseph Sedlak | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
22 Strathmore Road #415
Natick, MA, 01760
Natick, MA, 01760